Identification of key miRNA signature and pathways involved in multiple myeloma by integrated bioinformatics analysis-Reference-Cited by-同舟云学术

Identification of key miRNA signature and pathways involved in multiple myeloma by integrated bioinformatics analysis

Published:2021-01-01 Issue:1 Volume:26 Page:976-984
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Dong Xiushuai¹²,Lu Gang³,Su Xianwei³,Liu Jie¹,Chen Xi²,Tian Yaoyao²,Chang Yuying²,Wang Lianjie²,Wang Wei²,Zhou Jin¹

Affiliation:

1. Department of Hematology, The First Affiliated Hospital, Harbin Medical University, Harbin, People’s Republic of China

2. Department of Hematology, The Second Affiliated Hospital, Harbin Medical University, Harbin, People’s Republic of China

3. CUHK-SDU Joint Laboratory on Reproductive Genetics, School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong, People’s Republic of China

Publisher

Informa UK Limited

Subject

Hematology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/16078454.2021.2003980

Reference40 articles.

1. Multiple Myeloma

2. Evolutionary biology of high-risk multiple myeloma

3. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

4. Clinical treatment of newly diagnosed multiple myeloma

5. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expression levels and clinical significances of hsa-miR-29 family and their target genes in the bone marrow of patients with multiple myeloma;Indian Journal of Experimental Biology;2023-11-24

2. High serum miR-223-3p expression level predicts complete response and prolonged overall survival in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation;Frontiers in Oncology;2023-09-27

3. Investigating miR-9 as a mediator in laryngeal cancer health disparities;Frontiers in Oncology;2023-04-04